Moberg Pharma: Positive EU approval – launch delay push sales - Redeye

Redeye comments on the EU approval of MOB-015 and the new two-step approach to the EU launch. The delay incurred as related to the pan-European launch with the delay in sales also made it necessary to do an issue of SEK100m before costs. We will adjust our assumptions for the pushed European launch. In addition, we will further make tentative changes for the new issue, although the terms are unknown now.

Länk till analysen i sin helhet: https://www.redeye.se/research/918786/moberg-pharma-positive-eu-approval-launch-delay-push-sales?utm_source=finwire&utm_medium=RSS